Core Insights - ANI Pharmaceuticals, Inc. announced the presentation of results from the NEW DAY clinical trial of ILUVIEN® for diabetic macular edema at the American Academy of Ophthalmology 2025 Meeting [1][2] Group 1: Clinical Trial Results - The NEW DAY trial results will be presented in a late-breaking oral presentation titled "A Randomized, Active-Controlled Trial of Fluocinolone Acetonide 0.19mg Intravitreal Implant for Diabetic Macular Edema: The NEW DAY Study" [2] - The presentation is scheduled for October 17, 2025, at 4:39 pm ET during Retina Subspecialty Day 2025 [2] - Previous presentations of the NEW DAY results have occurred at various medical meetings earlier this year [3] Group 2: Product Information - ILUVIEN is indicated for the treatment of diabetic macular edema in patients previously treated with corticosteroids without a significant rise in intraocular pressure [3] - The product is a corticosteroid delivered via an intravitreal implant [1] Group 3: Company Overview - ANI Pharmaceuticals is focused on developing, manufacturing, and commercializing innovative therapeutics across various therapeutic areas, including ophthalmology [10] - The company aims for sustainable growth through its Rare Disease, Generics, and Brands business segments [10]